Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I: C

Papillomavirus Research

Volumn 1, Issue , 2015, Pages 12-21

  Da Silva, Diane M ^a,b,f   Woodham, Andrew W ^b   Rijkee, Laurie K ^c   Skeate, Joseph G ^a   Taylor, Julia R ^b   Koopman, Maaike E ^c   Brand, Heike E ^a   Wong, Michael K ^b   McKee, Greg M ^d   Salazar, Andres M ^e   Kast, W Martin ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Akela Pharma   (United States)

^e Oncovir Inc   (United States)

^f NONE   (United States)

Author keywords

HPV16; Immune escape; Langerhans cells; Papillomavirus

Indexed keywords

CHEMOKINE; CYTOKINE; POLYINOSINIC POLYCYTIDYLIC ACID;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; LANGERHANS CELL; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS LIKE AGENT; VIRUS PARTICLE;

EID: 84947915984     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2015.05.001     Document Type: Article

References (51)

1. Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., Vignat J., Ferlay J., Bray F., Plummer M., Franceschi S. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl. 5):F12-F23.
2. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 2007, 121:621-632.
3. Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C., Bratti M.C., Sherman M.E., Morales J., Guillen D., Alfaro M., Hutchinson M., Wright T.C., Solomon D., Chen Z., Schussler J., Castle P.E., Burk R.D. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337:76-84.
4. Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R., Abrahamsen M., Inserra P., Olvera S., Hatch K. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J. Infect. Dis. 2002, 186:462-469.
5. Rositch A.F., Koshiol J., Hudgens M.G., Razzaghi H., Backes D.M., Pimenta J.M., Franco E.L., Poole C., Smith J.S. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int. J. Cancer 2013, 133:1271-1285.
6. Fausch S.C., Da Silva D.M., Rudolf M.P., Kast W.M. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol. 2002, 169:3242-3249.
7. Fausch S.C., Fahey L.M., Da Silva D.M., Kast W.M. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J. Immunol. 2005, 174:7172-7178.
8. Da Silva D., Movius C., Raff A., Brand H., Skeate J., Wong M., Kast W. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a μ genotype. Virology 2014, 452-453:279-286.
9. Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 2008, 8:935-947.
10. Malissen B., Tamoutounour S., Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat. Rev. Immunol. 2014, 14:417-428.
11. Allan R.S., Smith C.M., Belz G.T., van Lint A.L., Wakim L.M., Heath W.R., Carbone F.R. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 2003, 301:1925-1928.
12. Kaplan D.H., Jenison M.C., Saeland S., Shlomchik W.D., Shlomchik M.J. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005, 23:611-620.
13. Bobr A., Olvera-Gomez I., Igyarto B.Z., Haley K.M., Hogquist K.A., Kaplan D.H. Acute ablation of Langerhans cells enhances skin immune responses. J. Immunol. 2010, 185:4724-4728.
14. Shklovskaya E., O'Sullivan B.J., Ng L.G., Roediger B., Thomas R., Weninger W. Fazekas de St Groth B: Langerhans cells are precommitted to immune tolerance induction. Proc. Natl. Acad. Sci. USA 2011, 108:18049-18054.
15. Flacher V., Tripp C.H., Mairhofer D.G., Steinman R.M., Stoitzner P., Idoyaga J., Romani N. Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance. EMBO Mol. Med. 2014, 6:1191-1204.
16. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., Briere F., Chaussabel D., Zurawski G., Palucka A.K., Reiter Y., Banchereau J., Ueno H. Functional specializations of human epidermal langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29:497-510.
17. Ratzinger G., Baggers J., de Cos M.A., Yuan J., Dao T., Reagan J.L., Munz C., Heller G., Young J.W. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J. Immunol. 2004, 173:2780-2791.
18. Polak M.E., Newell L., Taraban V.Y., Pickard C., Healy E., Friedmann P.S., Al-Shamkhani A., Ardern-Jones M.R. CD70-CD27 interaction augments CD8+ T-cell activation by human epidermal Langerhans cells. J. Invest. Dermatol. 2012, 132:1636-1644.
19. Fahey L.M., Raff A.B., Da Silva D.M., Kast W.M. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J. Immunol. 2009, 182:2919-2928.
20. Cheng Y.S., Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol. Ther. 2010, 10:1219-1223.
21. Flacher V., Bouschbacher M., Verronese E., Massacrier C., Sisirak V., Berthier-Vergnes O., de Saint-Vis B., Caux C., Dezutter-Dambuyant C., Lebecque S., Valladeau J. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol. 2006, 177:7959-7967.
22. Kawai T., Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann. NY Acad. Sci. 2008, 1143:1-20.
23. Matsumoto M., Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 2008, 60:805-812.
24. Furio L., Billard H., Valladeau J., Peguet-Navarro J., Berthier-Vergnes O. Poly(I:C)-treated human langerhans cells promote the differentiation of CD4+ T cells producing IFN-gamma and IL-10. J. Invest. Dermatol. 2009, 129:1963-1971.
25. Vercammen E., Staal J., Beyaert R. Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin. Microbiol. Rev. 2008, 21:13-25.
26. de Clercq E. Degradation of poly(inosinic acid)-poly(cytidylic acid) [(I)n-(C)n] by human plasma. Eur J Biochem./FEBS 1979, 93:165-172.
27. Levy H.B., Baer G., Baron S., Buckler C.E., Gibbs C.J., Iadarola M.J., London W.T., Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 1975, 132:434-439.
28. Greenstone H.L., Nieland J.D., de Visser K.E., De Bruijn M.L., Zkirnbauer R., Roden R.B.S., Lowy D.R., Kast W.M., Schiller J.T. Chimeric papillomavirus virus-like particles elicit antitumor immunity against E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA 1998, 95:1800-1805.
29. Woodham A.W., Raff A.B., Da Silva D.M., Kast W.M. Molecular analysis of human papillomavirus virus-like particle activated langerhans cells in vitro. Methods Mol. Biol. 2015, 1249:135-149.
30. Yan L., Woodham A.W., Da Silva D.M., Kast W.M. Functional analysis of HPV-like particle-activated langerhans cells in vitro. Methods Mol. Biol. 2015, 1249:333-350.
31. Muul L.M., Silvin C., James S.P., Candotti F. Measurement of proliferative responses of cultured lymphocytes. Curr Protocols Immunol 2008, (Chapter 7:Unit 7 10 11-17 10 24). J.E. Coligan (Ed.).
32. Rudolf M.P., Fausch S.C., Da Silva D.M., Kast W.M. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 2001, 166:5917-5924.
33. Randolph G.J., Ochando J., Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Ann. Rev. Immunol. 2008, 26:293-316.
34. Stingl G., Katz S.I., Clement L., Green I., Shevach E.M. Immunologic functions of Ia-bearing epidermal Langerhans cells. J. Immunol. 1978, 121:2005-2013.
35. Kast W.M., Brandt R.M., Sidney J., Drijfhout J.W., Kubo R.T., Grey H.M., Melief C.J., Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 1994, 152:3904-3912.
36. Prins R.M., Soto H., Konkankit V., Odesa S.K., Eskin A., Yong W.H., Nelson S.F., Liau L.M. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Can. Res. 2011, 17:1603-1615.
37. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., Mintz A.H., Engh J.A., Bartlett D.L., Brown C.K., Zeh H., Holtzman M.P., Reinhart T.A., Whiteside T.L., Butterfield L.H., Hamilton R.L., Potter D.M., Pollack I.F., Salazar A.M., Lieberman F.S. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 2011, 29:330-336.
38. Salazar A.M., Erlich R.B., Mark A., Bhardwaj N., Herberman R.B. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol. Res. 2014, 2:720-724.
39. Stanley M.A. Epithelial cell responses to infection with human papillomavirus. Clin. Microbiol. Rev. 2012, 25:215-222.
40. Lenz P., Day P.M., Pang Y.Y., Frye S.A., Jensen P.N., Lowy D.R., Schiller J.T. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 2001, 166:5346-5355.
41. Woodham A.W., Raff A.B., Raff L.M., Da Silva D.M., Yan L., Skeate J.G., Wong M.K., Lin Y.G., Kast W.M. Inhibition of langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J. Immunol. 2014, 192:4748-4757.
42. Fahey L.M., Raff A.B., Da Silva D.M., Kast W.M. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J. Immunol. 2009, 183:6151-6156.
43. Crozat K., Guiton R., Guilliams M., Henri S., Baranek T., Schwartz-Cornil I., Malissen B., Dalod M. Comparative genomics as a tool to reveal functional equivalences between human and mouse dendritic cell subsets. Immunol. Rev. 2010, 234:177-198.
44. Artyomov M.N., Munk A., Gorvel L., Korenfeld D., Cella M., Tung T., Klechevsky E. Modular expression analysis reveals functional conservation between human Langerhans cells and mouse cross-priming dendritic cells. J. Exp. Med. 2015.
45. Romani N., Brunner P.M., Stingl G. Changing views of the role of Langerhans cells. J. Invest. Dermatol. 2012, 132:872-881.
46. van der Aar A.M., de Groot R., Sanchez-Hernandez M., Taanman E.W., van Lier R.A., Teunissen M.B., de Jong E.C., Kapsenberg M.L. Cutting edge: virus selectively primes human langerhans cells for CD70 expression promoting CD8+ T cell responses. J. Immunol. 2011, 187:3488-3492.
47. Renn C.N., Sanchez D.J., Ochoa M.T., Legaspi A.J., Oh C.K., Liu P.T., Krutzik S.R., Sieling P.A., Cheng G., Modlin R.L. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J. Immunol. 2006, 177:298-305.
48. Domingos-Pereira S., Decrausaz L., Derre L., Bobst M., Romero P., Schiller J.T., Jichlinski P., Nardelli-Haefliger D., Intravaginal T.L.R. agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol. 2013, 6:393-404.
49. Andersen J.M., Al-Khairy D., Ingalls R.R. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol. Reprod. 2006, 74:824-831.
50. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., Salazar A.M., Uberla K., Nieto K., Kleinschmidt J., Schulte R., Gissmann L., Muller M., Sacher A., Racz P., Steinman R.M., Uguccioni M., Ignatius R. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 2009, 5:e1000373.
51. Caskey M., Lefebvre F., Filali-Mouhim A., Cameron M.J., Goulet J.P., Haddad E.K., Breton G., Trumpfheller C., Pollak S., Shimeliovich I., Duque-Alarcon A., Pan L., Nelkenbaum A., Salazar A.M., Schlesinger S.J., Steinman R.M., Sekaly R.P. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011, 208:2357-2366.